Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 713

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 713
---
 America and, once approved on a country -by-countrybasis, for commercializing Nolazol in Latin America. Furthermore, the marketing approvals obtained in Latin America, if any, shall be owned by Eurofarma until the end of the term of the EF License Agreement. Annex F-66

Upon the execution of the EF License Agreement, Eurofarma paid us $2.5 million. In accordance with the EF License Agreement, we are eligible to receive milestone payments as well as royalties from Eurofarma, which consist of the following: Clinical Milestones

| Upon successful completion by us of Phase 3 clinical trials for the treatment of ADHD in adults in the United States   |     | $ | 500,000 |
| Upon successful completion by us of Phase 3 clinical trials for the treatment of ADHD in children in the United States |     | $ | 500,000 |

Regulatory Milestones

| Upon price approval of the licensed product in Brazil by the relevant agency                                            |     | $ | 1,000,000 |
| Upon receipt of marketing approval by the relevant agency of the licensed product in any other country in Latin America |     | $ | 1,000,000 |

Sales Milestones (single payments)

| Upon reaching annual net sales of $10 million  |     | $ | 1,000,000 |
| Upon reaching annual net sales of $50 million  |     | $ | 2,000,000 |
| Upon reaching annual net sales of $75 million  |     | $ | 4,000,000 |
| Upon reaching annual net sales of $100 million |     | $ | 6,000,000 |

Royalties

| Annual net sales in Latin America    |     |     Royalties 
 in percent of 
     Net Sales |   |
| Under $10 million                    |     |             7 | % |
| $10 million to less than $20 million |     |             8 | % |
| $20 million to less than $30 million |     |             9 | % |
| $30 million and above                |     |            10 | % |

License Agreement with Novartis On March 10, 2021, we entered into a License Agreement with Novartis Pharma AG or Novartis, whereby we obtained, on an exclusive basis in the U.S., all of the available data referred to and included in the original NDA for Sanorex ®(mazindol)